Recent Company News

• 02:08 AM ET Jul 22, 2025
  

  BioArctic partner Eisai will present the latest findings on lecanemab (Leqembi), including four-year efficacy and safety data and data on the subcutaneous formulation for maintenance dosing at AAIC 2025 (SEK 196.00, 0.00)

• 01:03 AM ET Jul 09, 2025
  

  Price of Eisai's LEQEMBI to be cut by up to 15% in Japan following MHLW report (10:00 JST/22:00 ET/03:00 CET) (¥4033.0000, +33)

• 02:37 AM ET Jul 08, 2025
  

  Medivir receives Notice of Allowance for fostrox plus lenvatinib combination patent by Japan Patent Office (SEK 1.52, 0.00)

• 09:13 AM ET Jun 30, 2025
  

  FDA publishes FAERS for Q1 of 2025

• 06:08 PM ET Jun 20, 2025
  

  FDA grants orphan drug designation to Eisai compound for malaria (¥3944.0000, 0)

• 08:16 AM ET Jun 19, 2025
  

  Final draft guidance finds benefits of donanemab and lecanemab remain too small to justify the additional cost to the NHS -- NICE (earlier)

• 11:23 AM ET Jun 10, 2025
  

  Eisai upgraded to neutral from underperform at Daiwa (¥4018.0000, 0)

• 07:44 PM ET May 28, 2025
  

  Eisai receives favorable decision in patent infringement litigation regarding Lenvatinib in the US (¥3926.0000, 0)

• 12:13 AM ET May 27, 2025
  

  Eisai receives approval for in-house developed anti-insomnia drug DAYVIGO in China (¥3914.0000, +44)

• 02:00 PM ET May 16, 2025
  

  FDA approves first blood test for AD diagnosis